Evolent Health, Inc.

Evolent Health's capital structure shows a debt-to-equity ratio of 2.46, indicating a significant reliance on debt financing. The company's liquidity position is characterized by a current ratio of 1.32, suggesting moderate short-term liquidity. However, the operating cash flow of -$984,000 indicates a cash outflow from operations, which could be a concern for maintaining liquidity. In terms of profitability, the company reported a net loss of $26.6 million and an operating loss of $10.6 million for Q1 2026. The return on equity (ROE) is -6.72%, and the return on assets (ROA) is -1.42%, both significantly below the industry median for pharmaceutical companies. These metrics suggest that the company is not generating returns that meet industry standards. Evolent Health's revenue is concentrated among a few large partners, with the significant portion of revenue derived from its largest partners. This concentration poses a risk as the potential loss, termination, or renegotiation of relationships with these partners could materially impact the company's financial performance. The company's growth trajectory is mixed. While it has sufficient liquidity to meet its working capital and capital expenditure requirements for at least the next twelve months, the net loss and negative operating cash flow indicate challenges in achieving profitability. The company's ability to attract new partners and successfully capture new opportunities will be critical for future growth. Risk factors include the potential for dilution due to the company's obligations under the tax receivables agreement and the conditional conversion features of its notes. The dilution potential is further exacerbated by the company's need to raise funds to settle conversions of its notes in cash. The risk assessment indicates a medium level of dilution risk. Recent events include the backfilling of short-term debt data in the company's filings and the disclosure of forward-looking statements related to the company's ability to weather current dynamics and expand its footprint. The company also faces risks related to audits by CMS and other governmental payers, as well as the evolution of the healthcare regulatory and political framework.